Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of “Hold” by Analysts

Genmab A/S (NASDAQ:GMAB) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $45.20.

A number of analysts recently commented on GMAB shares. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Friday. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. Truist Financial reduced their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC purchased a new stake in Genmab A/S during the second quarter valued at about $1,354,000. Point72 Asset Management L.P. acquired a new position in shares of Genmab A/S in the 2nd quarter valued at about $457,000. Cubist Systematic Strategies LLC grew its holdings in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Up 1.5 %

Shares of Genmab A/S stock opened at $26.90 on Wednesday. The company has a 50-day moving average of $27.25 and a two-hundred day moving average of $28.06. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $38.80. The stock has a market cap of $17.79 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, sell-side analysts forecast that Genmab A/S will post 1.27 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.